Effect of recombinant @entity1 XXXX coupled with @entity968 on the platelet storage lesion.

@entity26118 @entity1 @entity20096 @entity44510 @entity8729 @entity2975 @entity880 @entity413 @entity970 @entity968
BACKGROUND: Platelet production is regulated by a thrombopoietic growth factor ( @entity26118 ). The receptor for this platelet growth factor ( @entity20096 ) is expressed on the platelet surface membrane. A recombinant thrombopoietic cytokine, recombinant @entity1 @entity26118 coupled with @entity968 ( @entity970 -rHuMGDF), was added to apheresis platelets in vitro to determine whether @entity20096 ligand-receptor binding produced any beneficial or adverse effect on the development of the platelet storage lesion during 5 days of storage. STUDY DESIGN AND METHODS: This study was designed as a dose-response protocol to determine the effects of adding increasing concentrations of @entity44510 (0.0 [control], 2.5, 25, and 250 ng/mL) to apheresis platelets stored in two types of plastic storage containers. The increasing concentrations of @entity970 -rHuMGDF used simulated the theoretical peak plasma level attained in vivo, with an intravenous dose of 0, 0.1, 1.0 and 10 microg per kg of @entity970 -rHuMGDF. The platelets were stored with agitation at 20 to 24 degrees C for 5 days. A battery of in vitro assays was performed on storage Days 1 and 5, including pH, blood gases, platelet count, @entity880 dehydrogenase, mean platelet volume, @entity413 , @entity880 , osmotic recovery, morphology score, @entity8729 , and one-dimensional @entity2975 gel electrophoresis analyses. RESULTS: Analysis of results on both Day 1 and Day 5 showed no significant differences among any of the three @entity970 -rHuMGDF doses and the control group, for any in vitro assay. One-dimensional @entity2975 gel electrophoresis showed no changes among the platelet protein patterns for the three @entity970 -rHuMGDF doses studied or the control. Storage-induced changes, however, did occur equally in all four groups of platelets over the 5 days of storage. CONCLUSION: The addition to stored apheresis platelets of up to 10 microg per kg of @entity970 -rHuMGDF (250 ng/mL), followed by 5 days of storage at standard conditions, does not appear to promote or retard development of the platelet storage lesion.
